Targeting Oncogenic RAS Protein
Dan L. Longo, Neal Rosen
Abstract
The authors examine the science behind the induction of objective responses in patients with NSCLC who received adagrasib, an inhibitor of a mutant version of KRAS, which was previously thought to be “undruggable.”
Topics & Concepts
MedicineKRASMutantCancer researchMutationOncologyBioinformaticsCancerGeneticsComputational biologyInternal medicineGeneBiologyColorectal cancerChronic Lymphocytic Leukemia ResearchCell death mechanisms and regulationDNA Repair Mechanisms